-zomib
A proteasome inhibitor, jamming the machinery cells use to break down proteins; used in multiple myeloma.
- Drugs ending in -zomib: 9
- Approved somewhere: 4
- With a US drug page: 4
- Stem
- -zomib
- Class
- Cancer drugs that jam the proteasome, like bortezomib
- Most common targets
- 26S proteasome (5), 20S proteasome (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -zomib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Bortezomib | Approved | 26S proteasome | 26S proteasome inhibitor |
| Carfilzomib | Approved | 26S proteasome | 26S proteasome inhibitor |
| Ixazomib | Approved | 26S proteasome | 26S proteasome inhibitor |
| Ixazomib citrate | Approved | 26S proteasome | 26S proteasome inhibitor |
| Marizomib | Phase 3 | 20S proteasome | 20S proteasome inhibitor |
| Davelizomib | Phase 2 | — | — |
| Zetomipzomib | Phase 2 | — | — |
| Delanzomib | Phase 1 | — | — |
| Oprozomib | Phase 1 | 26S proteasome | 26S proteasome inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO